阿瑞匹坦对睾丸癌患者依托泊苷药代动力学的影响
本研究为前瞻性观察性研究,纳入12例接受一线化疗的睾丸癌患者,比较联用与不联用阿瑞匹坦时依托泊苷的药代动力学。结果显示依托泊苷AUC0-24h几何均值比为1.03(90%CI 0.96-1.10),Cmax几何均值比为0.96(90%CI 0.89-1.03),证实两者无临床相关相互作用,可安全联用。
要点
- 阿瑞匹坦与依托泊苷联用不显著改变依托泊苷的AUC0-24h和Cmax。
- 联用阿瑞匹坦时依托泊苷AUC0-24h几何均值为86.2(79.7-93.2)mg/L*hour。
- 两药可安全联用,无需因相互作用调整依托泊苷暴露。
核心结论
- 阿瑞匹坦与依托泊苷之间不存在临床相关的药物相互作用。
- 两药联用不影响依托泊苷的系统暴露,可安全组合。
研究设计与样本
- 前瞻性观察性研究,纳入12例接受一线化疗的睾丸癌患者。
- 比较联用与不联用阿瑞匹坦时依托泊苷的药代动力学参数。
主要发现
- 联用阿瑞匹坦时依托泊苷AUC0-24h几何均值为86.2(79.7-93.2)mg/L*hour,不联用时为83.7(75.8-92.4)mg/L*hour。
- AUC0-24h几何均值比为1.03(90%CI 0.96-1.10)。
- Cmax几何均值比为0.96(90%CI 0.89-1.03)。
临床怎么用
- 临床可考虑将阿瑞匹坦与依托泊苷联用,无需担心影响依托泊苷暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
All patients treated with anticancer agents should receive the most effective anti-emetic regimen. Anti-emetic guidelines provide recommendations but do not take into account possible drug-drug interactions between anti-emetics and anticancer drugs. This study determines the clinical relevance of the potential drug-drug interaction of the neurokinin-1 receptor antagonist, aprepitant, on the pharmacokinetics of etoposide. Aprepitant is a moderate CYP3A4 inhibitor and may increase the systemic exposure of etoposide which is partly metabolized by cytochrome P450 enzyme 3A4 (CYP3A4). In this prospective observational study, the pharmacokinetics of etoposide with and without concomitant use of aprepitant was determined in 12 patients receiving first-line chemotherapy for testicular cancer. The geometric mean (95% confidence interval (CI)) area under the plasma concentration-time curve 0-24 hour (AUC0-24h ) of etoposide with aprepitant was 86.2 (79.7-93.2) mg/L*hour vs. 83.7 (75.8-92.4) mg/L*hour without aprepitant. Geometric mean ratios (90% CIs) of AUC0-24h and maximum plasma concentration (Cmax ) for etoposide with and without aprepitant were 1.03 (0.96-1.10) and 0.96 (0.89-1.03), respectively. This study confirms the absence of a clinically relevant interaction between etoposide and aprepitant. Both drugs can be safely combined without affecting etoposide exposure.
引用
- Strik J, de Jong LAW, Sijm J, et al. Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction. Clin Pharmacol Ther. 2023. PMID: 37867292. doi:10.1002/cpt.3081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。